Immunovant Stock Plunges On $200M Equity Investment From Roivant To Support IMVT-1401 Development

  • Immunovant Inc IMVT has received a $200 million strategic investment from Roivant Sciences that the Company will use to advance IMVT-1401 in multiple indications.
  • Roivant has purchased around 17 million shares of Immunovant's shares at $11.75 per share. 
  • After giving effect to the investment, Immunovant has a pro forma cash balance of approximately $600 million, and Roivant has increased its ownership stake in Immunovant from 57.5% to 63.8%.
  • IMVT-1401, a fully human anti-FcRn monoclonal antibody, is Immunovant's lead candidate.
  • "We are excited to announce this significant investment by Roivant, which will expedite our development of IMVT-1401 for a wide range of autoimmune disorders," said Dr. Pete Salzmann, Chief Executive Officer of Immunovant. "Over the next 12 months, we plan to initiate a pivotal trial for myasthenia gravis, resume our trials in WAIHA and TED and initiate at least two additional clinical studies, including another pivotal trial in 2022."
  • Price Action: IMVT shares are down 24.5% at $7.90 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsShort IdeasHealth CareFinancingOfferingsSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!